(Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Opinions expressed are those of the author. Membership (fee-based) Shanna Apitz, President + Chief Creative Officer of Hunt Adkins, champions business growth through art, science and kicking ...

LATEST NEWS 05:00 How to pick the life insurance policy that’s right for you 05:00 Dublin AI start-up Glitch set to launch online ad platform 05:00 Movers & Shakers: MSD Ireland, Edelman, Ergo, Fáilte ...

NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

As Humira sales plummeted 32% during the first half of 2024, AbbVie saw revenue for its neuroscience drugs increase 15% during the same period. Neuroscience is one of the three main pillars of its new ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.